| Bioactivity | Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD)[1][2]. | ||||||||||||
| Invitro | In vitro, Naxagolide ((+)-PHNO) inhibits binding of [3H]apomorphine (IC50 = 23 nM) or [3H]spiperone (IC50 = 55 nM) to rat striatal membranes[1]. | ||||||||||||
| In Vivo | In mice, Naxagolide ((+)-PHNO) produces hypothermia (13 μg/kg i.p.) and postural asymmetry in the unilaterally caudectomized animal (4 μg/kg i.p.)[1]. In the rat, Naxagolide ((+)-PHNO) produces stereotypy (10 μg/kg i.p.) and contralateral turning in 6-hydroxydopamine-lesioned animals (5 μg/kg i.p.) that lasted 1 to 3 hr[1]. | ||||||||||||
| Name | Naxagolide | ||||||||||||
| CAS | 88058-88-2 | ||||||||||||
| Formula | C15H21NO2 | ||||||||||||
| Molar Mass | 247.33 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. G E Martin, et al. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]. J Pharmacol Exp Ther. 1984 Sep;230(3):569-76. [2]. E F Domino, et al. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther. 1993 Jun;265(3):1387-91. |